Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) started the day on March 04, 2021, with a price decrease of -6.75% at $13.41. During the day, the stock rose to $14.40 and sunk to $13.19 before settling in for the price of $14.38 at the close. Taking a more long-term approach, AUPH posted a 52-week range of $9.83-$20.50.
Nevertheless, stock’s Earnings Per Share (EPS) this year is -53.00%. This publicly-traded company’s shares outstanding now amounts to $127.45 million, simultaneously with a float of $115.31 million. The organization now has a market capitalization sitting at $1.71 billion. At the time of writing, stock’s 50-day Moving Average stood at $14.90, while the 200-day Moving Average is $14.84.
It has generated 6,806 per worker during the last fiscal year. Meanwhile, its income per employee was -2,650,499. The stock had 1.09 Receivables turnover and 0.00 Total Asset turnover. For the Profitability, stocks operating margin was -23977.99 and Pretax Margin of -38900.00.
Aurinia Pharmaceuticals Inc. (AUPH) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Aurinia Pharmaceuticals Inc.’s current insider ownership accounts for 9.77%, in contrast to 55.87% institutional ownership. According to the most recent insider trade that took place on Jan 29, this organization’s Director bought 400 shares at the rate of 16.03, making the entire transaction reach 6,412 in total value, affecting insider ownership by 400. Preceding that transaction, on Jan 29, Company’s Director bought 1,200 for 16.03, making the whole transaction’s value amount to 19,236. This particular insider is now the holder of 1,200 in total.
Aurinia Pharmaceuticals Inc. (AUPH) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 9/29/2017, the organization reported -$0.16 earnings per share (EPS) for the three months, lower than the consensus estimate (set at -$0.15) by -$0.01. This company achieved a net margin of -38945.28 while generating a return on equity of -64.64. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
Aurinia Pharmaceuticals Inc.’s EPS decrease for this current 12-month fiscal period is -53.00% and is forecasted to reach -0.55 in the upcoming year.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Trading Performance Indicators
Let’s observe the current performance indicators for Aurinia Pharmaceuticals Inc. (AUPH). The Stock has managed to achieve an average true range (ATR) of 0.90. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 34.10.
In the same vein, AUPH’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.87, a figure that is expected to reach -0.14 in the next quarter, and analysts are predicting that it will be -0.55 at the market close of one year from today.
Technical Analysis of Aurinia Pharmaceuticals Inc. (AUPH)
If we take a close look at the recent performances of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), its last 5-days Average volume was 3.9 million that shows plunge from its year to date volume of 5.33 million. During the previous 9 days, stock’s Stochastic %D was recorded 18.98% While, its Average True Range was 0.84.
Raw Stochastic average of Aurinia Pharmaceuticals Inc. (AUPH) in the period of the previous 100 days is set at 9.62%, which indicates a major rise in contrast to 7.26% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 45.48% that was lower than 71.22% volatility it exhibited in the past 100-days period.